Skip to main content

CORRECTION article

Front. Aging Neurosci., 02 August 2023
Sec. Cellular and Molecular Mechanisms of Brain-aging
Volume 15 - 2023 | https://doi.org/10.3389/fnagi.2023.1250440

Corrigendum: CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease

This article is a correction to:

  1. CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease

    1. Read original article
\r\nRui Wang&#x;Rui Wang1†Shanshan Tong&#x;Shanshan Tong1†Mengdi WangMengdi Wang1Junjie ZouJunjie Zou2Nan WangNan Wang3Fengjiao SunFengjiao Sun3Xiaosheng Zhou Xiaosheng Zhou1*Jinbo ChenJinbo Chen1Hongcai Wang Hongcai Wang1*
  • 1Department of Neurology, Binzhou Medical University Hospital, Binzhou, Shandong, China
  • 2Department of Neurology, Penglai People's Hospital, Yantai, China
  • 3Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong, China

A corrigendum on
CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease

by Wang, R., Tong, S., Wang, M., Zou, J., Wang, N., Sun, F., Zhou, X., Chen, J., and Wang, H. (2023). Front. Aging Neurosci. 15:1122647. doi: 10.3389/fnagi.2023.1122647

In the published article, there was an error in Figure 5A, Image d as published. We inadvertently used the wrong figure and need to correct the Figure 5A, Image d. The other elements of the Figure 5 remain the same. The corrected Figure 5A, Image d and its caption appear below.

FIGURE 5
www.frontiersin.org

Figure 5. GM1 prevented ROT-induced cell apoptosis. (A, B) Impaired neurite outgrowth was inhibited by GM1 addition. Scale bar = 10 μm. (C, D) GM1 decreased ROT-induced cell apoptosis. *P < 0.05; ****P < 0.0001; #,##P > 0.05.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: monosialotetrahexosylganglioside (GM1), Parkinson's disease (PD), DNA methylation, rotenone (ROT), cell apoptosis

Citation: Wang R, Tong S, Wang M, Zou J, Wang N, Sun F, Zhou X, Chen J and Wang H (2023) Corrigendum: CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease. Front. Aging Neurosci. 15:1250440. doi: 10.3389/fnagi.2023.1250440

Received: 30 June 2023; Accepted: 24 July 2023;
Published: 02 August 2023.

Edited and reviewed by: Jorge Busciglio, University of California, Irvine, United States

Copyright © 2023 Wang, Tong, Wang, Zou, Wang, Sun, Zhou, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hongcai Wang, whc2891@126.com; Xiaosheng Zhou, zhouxiaosheng001@126.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.